Mineralys Therapeutics, Inc.
NasdaqGS MLYS
Mineralys Therapeutics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024
Mineralys Therapeutics, Inc. Return on Equity (ROE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
Key data
| Date | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio |
|---|
Market news
Loading...
NasdaqGS: MLYS
| CEO | Mr. Jon Congleton |
| IPO Date | Feb. 10, 2023 |
| Location | United States |
| Headquarters | 150 N. Radnor Chester Rd. |
| Employees | 28 |
| Sector | Health Care |
| Industries | |
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email